CA3226397A1 - Therapeutic muteins - Google Patents
Therapeutic muteins Download PDFInfo
- Publication number
- CA3226397A1 CA3226397A1 CA3226397A CA3226397A CA3226397A1 CA 3226397 A1 CA3226397 A1 CA 3226397A1 CA 3226397 A CA3226397 A CA 3226397A CA 3226397 A CA3226397 A CA 3226397A CA 3226397 A1 CA3226397 A1 CA 3226397A1
- Authority
- CA
- Canada
- Prior art keywords
- mutein
- seq
- cytokine
- amino acid
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2110547.3A GB202110547D0 (en) | 2021-07-22 | 2021-07-22 | Therapeutic muteins |
| GB2110547.3 | 2021-07-22 | ||
| FR2203600 | 2022-04-19 | ||
| FR2203600 | 2022-04-19 | ||
| PCT/EP2022/070548 WO2023001987A2 (en) | 2021-07-22 | 2022-07-21 | Therapeutic muteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226397A1 true CA3226397A1 (en) | 2023-01-26 |
Family
ID=82942857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226397A Pending CA3226397A1 (en) | 2021-07-22 | 2022-07-21 | Therapeutic muteins |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240352084A1 (https=) |
| EP (1) | EP4373848A2 (https=) |
| JP (1) | JP2024527629A (https=) |
| CA (1) | CA3226397A1 (https=) |
| IL (1) | IL310292A (https=) |
| WO (1) | WO2023001987A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023249425A1 (ko) * | 2022-06-22 | 2023-12-28 | ㈜지아이이노베이션 | 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| AU2024330564A1 (en) | 2023-08-30 | 2026-04-02 | Xilio Development, Inc. | Vhh masked cytokines and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569215B2 (en) * | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CA3007135A1 (en) | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| US20180339043A1 (en) | 2017-05-26 | 2018-11-29 | Janux Therapeutics, Inc. | Modified antibodies |
| US12202911B2 (en) | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| IL275426B2 (en) * | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| WO2019152413A1 (en) | 2018-02-02 | 2019-08-08 | Oncoimmune, Inc. | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| BR112020019083A2 (pt) | 2018-03-21 | 2020-12-29 | Five Prime Therapeutics, Inc. | Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer |
| US10597453B2 (en) | 2018-06-29 | 2020-03-24 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| CN119874917A (zh) | 2019-06-07 | 2025-04-25 | 阿迪马布有限责任公司 | 工程化的pH依赖性抗CD3抗体及其产生和使用方法 |
| KR102560876B1 (ko) | 2019-06-11 | 2023-07-28 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 항-epcam 항체, 항체 단편, 이들의 면역접합체 및 이의 용도 |
| PH12022550326A1 (en) | 2019-08-13 | 2023-03-13 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
-
2022
- 2022-07-21 EP EP22757224.5A patent/EP4373848A2/en active Pending
- 2022-07-21 WO PCT/EP2022/070548 patent/WO2023001987A2/en not_active Ceased
- 2022-07-21 CA CA3226397A patent/CA3226397A1/en active Pending
- 2022-07-21 US US18/290,928 patent/US20240352084A1/en active Pending
- 2022-07-21 JP JP2024503765A patent/JP2024527629A/ja active Pending
- 2022-07-21 IL IL310292A patent/IL310292A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024527629A (ja) | 2024-07-25 |
| WO2023001987A3 (en) | 2023-03-16 |
| EP4373848A2 (en) | 2024-05-29 |
| US20240352084A1 (en) | 2024-10-24 |
| IL310292A (en) | 2024-03-01 |
| WO2023001987A2 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7447232B2 (ja) | アルブミン結合ドメイン融合タンパク質 | |
| Saxton et al. | Emerging principles of cytokine pharmacology and therapeutics | |
| JP6941664B2 (ja) | 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体 | |
| JP7142630B2 (ja) | ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質 | |
| JP7846963B2 (ja) | 生物学的に関連する直交サイトカイン／受容体対 | |
| KR102609197B1 (ko) | 인터류킨 15 단백질 복합체 및 그의 용도 | |
| CN113286609B (zh) | 多聚体t细胞调节多肽及其使用方法 | |
| CN114901679A (zh) | 全新被掩蔽的细胞因子及其应用 | |
| KR20210021467A (ko) | 활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법 | |
| JP2018515085A (ja) | 抗がん融合ポリペプチド | |
| US20240352084A1 (en) | Therapeutic muteins | |
| KR20230009872A (ko) | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 | |
| Li et al. | Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21 | |
| Bick et al. | Targeting γc family cytokines with biologics: current status and future prospects | |
| AU2021296605A1 (en) | Cytokine conjugates | |
| TW202140562A (zh) | 雙特異性結合分子 | |
| CN118974101A (zh) | 一种pd1抗体与白介素2融合的双功能分子 | |
| KR20240057442A (ko) | 이중특이성 nk 세포 작용제, 제조 방법 및 응용 | |
| CN117999280A (zh) | 治疗性突变蛋白 | |
| JP2023521174A (ja) | インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体 | |
| US20250236653A1 (en) | Targeted low potency il-12 fc fusion proteins and uses thereof | |
| US20250288666A1 (en) | Methods and compositions for use in cell therapy of neoplastic disease | |
| RU2786444C2 (ru) | Слитые белки с альбумин-связывающими доменами | |
| Fisher | Improving CAR-T Cell Proliferation and Efficacy Using Cytokine Stimulation and Novel Fusion Protein Selection | |
| JP2025535705A (ja) | インターロイキン２１模倣体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250707 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250707 |